tradingkey.logo

Palvella Therapeutics Announces Positive Topline Results From Phase 2 TOIVA Clinical Trial Of Qtorin™

ReutersDec 15, 2025 11:19 AM

- Palvella Therapeutics Inc PVLA.O:

  • PALVELLA THERAPEUTICS ANNOUNCES POSITIVE TOPLINE RESULTS FROM PHASE 2 TOIVA CLINICAL TRIAL OF QTORIN™ 3.9% RAPAMYCIN ANHYDROUS GEL (QTORIN™ RAPAMYCIN) FOR THE TREATMENT OF CUTANEOUS VENOUS MALFORMATIONS, A SERIOUS, RARE GENETIC DISEASE WITH NO FDA-APPROVED THERAPIES

  • PALVELLA THERAPEUTICS INC - 73% OF PARTICIPANTS IMPROVED IN PHASE 2 TRIAL

  • PALVELLA THERAPEUTICS INC - QTORIN™ RAPAMYCIN WELL-TOLERATED WITH NO SERIOUS ADVERSE EVENTS

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.
Tradingkey

Related Articles

Tradingkey
KeyAI